Comparative Pharmacology
Head-to-head clinical analysis: JASCAYD versus TEPMETKO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JASCAYD versus TEPMETKO.
JASCAYD vs TEPMETKO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JASCAYD (tasquinimod) is a selective allosteric inhibitor of S100A9, which binds to toll-like receptor 4 (TLR4) and receptor for advanced glycation end-products (RAGE). It modulates the tumor microenvironment by inhibiting myeloid-derived suppressor cell (MDSC) recruitment and function, reducing angiogenesis, and enhancing anti-tumor immune responses.
Tepotinib is a highly selective, ATP-competitive inhibitor of the mesenchymal-epithelial transition (MET) receptor tyrosine kinase, including the MET exon 14 skipping variant. It inhibits MET phosphorylation and downstream signaling pathways, thereby reducing tumor cell proliferation and migration.
Adults: 300 mg orally twice daily with food.
450 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically relevant for once-daily dosing.
Terminal elimination half-life approximately 12-15 hours in patients, supporting twice-daily dosing.
Primarily renal excretion (80%) as unchanged drug; 20% fecal via biliary elimination.
Primarily fecal (≥80% of absorbed dose), with renal excretion accounting for <5% as unchanged drug.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor